The Catalog / The GLP-1 Reset
Transition brief · August 2026
The regulatory foundation under compounded GLP-1 programs has been dismantled in stages — and the last stage is closing now. This is the one-page brief for practices offering medical weight loss: what changed, the dates, and the three moves practices are making. No pitch attached.
Download the brief (PDF) One page · no email required · share it with your team| Date | Event |
|---|---|
| Dec 2024 / Feb 2025 | FDA declares the tirzepatide, then semaglutide, shortages resolved — ending the legal basis for compounded copies |
| 2025 | Federal courts deny compounders' injunctions; enforcement discretion ends for 503A and 503B |
| Sep 2025 – Jun 2026 | Three FDA enforcement waves: 100+ warning letters to telehealth and compounding operations |
| Feb 2026 | FDA Commissioner announces targeted enforcement: misleading ads, importation, bulk interstate shipping |
| Apr 30, 2026 | FDA proposes permanently excluding semaglutide, tirzepatide & liraglutide from the 503B Bulks List — the last large-scale pathway |
| Jul 30, 2026 | Public comment period closed. A final rule is the remaining step. |
Translation: "personalized dosing" and B12-added workarounds are exactly what the warning letters target. Practices still stocking compounded GLP-1 vials are carrying compliance risk that gets worse every month.
Compounded GLP-1s survived post-shortage because they were cheap. That advantage is gone:
An FDA-approved pill now costs what patients were paying for a gray-market vial. The question isn't whether to transition — it's whether your practice keeps those patients when they move.
Weight loss became the front door of the modern aesthetic practice: GLP-1 patients convert into long-term injectable, skin, and wellness patients. Roughly 4 in 10 US med spas now run a GLP-1 program. Losing the program doesn't just cut one revenue line — it cuts the acquisition channel feeding everything else.
Move 1
No practice-branded bulk vials, no "same as Ozempic" marketing language, documented patient-specific prescribing only. The most common enforcement triggers are also the easiest to fix.
Move 2
Authorized-distributor supply of approved GLP-1s (injectable and the new orals) keeps your patient pipeline and your prescribing revenue intact — thinner drug margin, zero regulatory cliff.
Move 3
While the GLP-1 door closes, the peptide door is opening: in April 2026 the FDA removed BPC-157, TB-500, and CJC-1295 from its restricted Category 2 list, and in July 2026 its compounding advisory committee voted to recommend six peptides — BPC-157 and TB-500 among them — for the 503A bulks list. The recommendation is non-binding and rulemaking remains (all seven tallies here), but demand is pent-up, and the practices building compliant peptide and longevity programs now will own the category locally when the unlock completes.
We help practices execute all three: compliance-clean medication supply, peptide and wellness program buildout, and the prescribing and operations infrastructure underneath. One 15-20 minute call maps your specific transition.
Map your transition with Justin
15-20 minutes · Zoom · no cost, no obligation
Pick a time →Prefer to talk now? 813-544-7131 · justin@eventideaw.com
Or grab the one-page PDF to share with your team.
Prepared by Justin Messner · Eventide Aesthetics & Wellness / Breakthrough Pharmacy Partners · August 2026 · Updated as the FDA acts
General market and regulatory information — not legal or medical advice. This brief summarizes public regulatory events and market pricing for licensed medical providers and practice owners. State requirements vary, and nothing here should be read as a claim that any medication or peptide is safe, effective, approved, or available for compounding. Compounded medications are not FDA-approved; the FDA does not review compounded medications for safety or efficacy. Eventide is not a pharmacy and does not manufacture, dispense, prescribe, or recommend any medication. Confirm compliance decisions with your healthcare attorney and state boards. No patient outcome is claimed or guaranteed.